| Literature DB >> 31316185 |
Armando Stabile1,2,3, Francesco Giganti4,5, Andrew B Rosenkrantz6, Samir S Taneja6,7, Geert Villeirs8, Inderbir S Gill9, Clare Allen5, Mark Emberton4,10, Caroline M Moore4,10, Veeru Kasivisvanathan4,10.
Abstract
The current diagnostic pathway for prostate cancer has resulted in overdiagnosis and consequent overtreatment as well as underdiagnosis and missed diagnoses in many men. Multiparametric MRI (mpMRI) of the prostate has been identified as a test that could mitigate these diagnostic errors. The performance of mpMRI can vary depending on the population being studied, the execution of the MRI itself, the experience of the radiologist, whether additional biomarkers are considered and whether mpMRI-targeted biopsy is carried out alone or in addition to systematic biopsy. A number of challenges to implementation remain, such as ensuring high-quality execution and reporting of mpMRI and ensuring that this diagnostic pathway is cost-effective. Nevertheless, emerging clinical trial data support the adoption of this technology as part of the standard of care for the diagnosis of prostate cancer.Entities:
Mesh：
Year: 2019 PMID： 31316185 DOI： 10.1038/s41585-019-0212-4
Source DB: PubMed Journal: Nat Rev Urol ISSN： 1759-4812 Impact factor: 14.432